Complement activation during liver transplantation-special emphasis on patients with atypical hemolytic uremic syndrome

American Journal of Transplantation

Volumn 11, Issue 9, 2011, Pages 1885-1895

  Koskinen, A R ^a,b   Tukiainen, E ^b   Arola, J ^a,b   Nordin, A ^b   Hockerstedt H K ^b   Nilsson, B ^c   Isoniemi, H ^b   Jokiranta, T S ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c UPPSALA UNIVERSITY   (Sweden)

Author keywords

Acute liver failure; complement; complement regulation; hemolytic uremic syndrome; hyperacute rejection; innate immunity; ischemia reperfusion injury; liver transplantation; primary biliary cirrhosis; primary sclerosing cholangitis

Indexed keywords

ALANINE AMINOTRANSFERASE; ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C3D; COMPLEMENT COMPONENT C4D; COMPLEMENT FACTOR H; COMPLEMENT FACTOR I; COMPLEMENT MEMBRANE ATTACK COMPLEX;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; COMPLEMENT ACTIVATION; COMPLEMENT ALTERNATIVE PATHWAY; COMPLEMENT BLOOD LEVEL; FEMALE; HEMOLYTIC UREMIC SYNDROME; HISTOLOGY; HUMAN; HUMAN TISSUE; KIDNEY TRANSPLANTATION; LIVER GRAFT; LIVER KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; LIVER VEIN; MALE; PATIENT MONITORING; PERIOPERATIVE PERIOD; PLASMAPHERESIS; PORTAL VEIN; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; PRIORITY JOURNAL; REPERFUSION; TREATMENT OUTCOME;

ADOLESCENT; ADULT; COMPLEMENT ACTIVATION; HEMOLYTIC-UREMIC SYNDROME; HUMANS; LIVER TRANSPLANTATION; MIDDLE AGED; YOUNG ADULT;

EID: 80052268538     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2011.03612.x     Document Type: Article

References (49)

1. Noris M, Remuzzi G,. Atypical hemolytic-uremic syndrome. N Engl J Med 2009; 361: 1676-1687.
2. Noris M, Caprioli J, Bresin E, et al., Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol 2010; 5: 1844-1859.
3. Warwicker P, Goodship TH, Donne RL, et al,. Genetic studies into inherited and sporadic hemolytic uremic syndrome. Kidney Int 1998; 53: 836-844. (Pubitemid 28155655)
4. Richards A, Buddles MR, Donne RL, et al,. Factor H mutations in hemolytic uremic syndrome cluster in exons 18-20, a domain important for host cell recognition. Am J Hum Genet 2001; 68: 485-490. (Pubitemid 32147817)
5. Perez-Caballero D, Gonzalez-Rubio C, Gallardo ME, et al., Clustering of missense mutations in the C-terminal region of factor H in atypical hemolytic uremic syndrome. Am J Hum Genet 2001; 68: 478-484. (Pubitemid 32147816)
6. Caprioli J, Bettinaglio P, Zipfel PF, et al,. The molecular basis of familial hemolytic uremic syndrome: Mutation analysis of factor H gene reveals a hot spot in short consensus repeat 20. J Am Soc Nephrol 2001; 12: 297-307. (Pubitemid 32116371)
7. Manuelian T, Hellwage J, Meri S, et al,. Mutations in factor H reduce binding affinity to C3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome. J Clin Invest 2003; 111: 1181-1190. (Pubitemid 36519935)
8. Ferreira VP, Herbert AP, Hocking HG, Barlow PN, Pangburn MK,. Critical role of the C-terminal domains of factor H in regulating complement activation at cell surfaces. J Immunol 2006; 177: 6308-6316. (Pubitemid 44628849)
9. Lehtinen MJ, Rops AL, Isenman DE, van der Vlag J, Jokiranta TS,. Mutations of factor H impair regulation of surface-bound C3b by three mechanisms in atypical hemolytic uremic syndrome. J Biol Chem 2009; 284: 15650-15658.
10. Fremeaux-Bacchi V, Dragon-Durey MA, Blouin J, et al,. Complement factor I: A susceptibility gene for atypical haemolytic uraemic syndrome. J Med Genet 2004; 41: e84.
11. Kavanagh D, Kemp EJ, Mayland E, et al,. Mutations in complement factor I predispose to development of atypical hemolytic uremic syndrome. J Am Soc Nephrol 2005; 16: 2150-2155. (Pubitemid 41716447)
12. Richards A, Kemp EJ, Liszewski MK, et al,. Mutations in human complement regulator, membrane cofactor protein (CD46), predispose to development of familial hemolytic uremic syndrome. Proc Natl Acad Sci U S A 2003; 100: 12966-12971. (Pubitemid 37340009)
13. Noris M, Brioschi S, Caprioli J, et al,. International Registry of Recurrent and Familial HUS/TTP. Familial haemolytic uraemic syndrome and an MCP mutation. Lancet 2003; 362: 1542-1547.
14. Fremeaux-Bacchi V, Miller EC, Liszewski MK, et al,. Mutations in complement C3 predispose to development of atypical hemolytic uremic syndrome. Blood 2008; 112: 4948-4952.
15. Goicoechea de Jorge E, Harris CL, Esparza-Gordillo J, et al,. Gain-of-function mutations in complement factor B are associated with atypical hemolytic uremic syndrome. Proc Natl Acad Sci U S A 2007; 104: 240-245. (Pubitemid 46068016)
16. Delvaeye M, Noris M, De Vriese A, et al,. Thrombomodulin mutations in atypical hemolytic-uremic syndrome. N Engl J Med 2009; 361: 345-357.
17. Nurnberger J, Philipp T, Witzke O, et al,. Eculizumab for atypical hemolytic-uremic syndrome. N Engl J Med 2009; 360: 542-544.
18. Chatelet V, Fremeaux-Bacchi V, Lobbedez T, Ficheux M, Hurault de Ligny B,. Safety and long-term efficacy of eculizumab in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome. Am J Transplant 2009; 9: 2644-2645.
19. Davin JC, Gracchi V, Bouts A, Groothoff J, Strain L, Goodship T,. Maintenance of kidney function following treatment with eculizumab and discontinuation of plasma exchange after a third kidney transplant for atypical hemolytic uremic syndrome associated with a CFH mutation. Am J Kidney Dis 2010; 55: 708-711.
20. Zimmerhackl LB, Hofer J, Cortina G, et al,. Prophylactic eculizumab after renal transplantation in atypical hemolytic-uremic syndrome. N Engl J Med 2010; 362: 1746-1748.
21. Bresin E, Daina E, Noris M, et al,. International Registry of Recurrent and Familial HUS/TTP. Outcome of renal transplantation in patients with non-Shiga toxin-associated hemolytic uremic syndrome: Prognostic significance of genetic background. Clin J Am Soc Nephrol 2006; 1: 88-99.
22. Loirat C, Fremeaux-Bacchi V,. Hemolytic uremic syndrome recurrence after renal transplantation. Pediatr Transplant 2008; 12: 619-629.
23. Noris M, Remuzzi G,. Thrombotic microangiopathy after kidney transplantation. Am J Transplant 2010; 10: 1517-1523.
24. Remuzzi G, Ruggenenti P, Codazzi D, et al,. Combined kidney and liver transplantation for familial haemolytic uraemic syndrome. Lancet 2002; 359: 1671-1672. (Pubitemid 34518531)
25. Cheong HI, Lee BS, Kang HG, et al,. Attempted treatment of factor H deficiency by liver transplantation. Pediatr Nephrol 2004; 19: 454-458. (Pubitemid 38477414)
26. Remuzzi G, Ruggenenti P, Colledan M, et al,. Hemolytic uremic syndrome: A fatal outcome after kidney and liver transplantation performed to correct factor h gene mutation. Am J Transplant 2005; 5: 1146-1150. (Pubitemid 40571267)
27. Saland JM, Emre SH, Shneider BL, et al., Favorable long-term outcome after liver-kidney transplant for recurrent hemolytic uremic syndrome associated with a factor H mutation. Am J Transplant 2006; 6 1948-1952. (Pubitemid 44024968)
28. Jalanko H, Peltonen S, Koskinen A, et al,. Successful liver-kidney transplantation in two children with aHUS caused by a mutation in complement factor H. Am J Transplant 2008; 8: 216-221.
29. Saland JM, Shneider BL, Bromberg JS, et al,. Successful split liver-kidney transplant for factor H associated hemolytic uremic syndrome. Clin J Am Soc Nephrol 2009; 4: 201-206.
30. Saland JM, Ruggenenti P, Remuzzi G, Consensus Study Group. Liver-kidney transplantation to cure atypical hemolytic uremic syndrome. J Am Soc Nephrol 2009; 20: 940-949.
31. Haller W, Milford DV, Goodship TH, Sharif K, Mirza DF, McKiernan PJ,. Successful isolated liver transplantation in a child with atypical hemolytic uremic syndrome and a mutation in complement factor H. Am J Transplant 2010; 10: 2142-2147.
32. Tomasdottir H, Henriksson BA, Bengtson JP, Bengtsson A, Stenqvist O, Persson H,. Complement activation during liver transplantation. Transplantation 1993; 55: 799-802. (Pubitemid 23122051)
33. Yassa SK, Blessios G, Marinides G, Venuto RC,. Anti-CD20 monoclonal antibody (Rituximab) for life-threatening hemolytic-uremic syndrome. Clin Transplant 2005; 19: 423-426. (Pubitemid 40711981)
34. Junnikkala S, Hakulinen J, Jarva H, et al,. Secretion of soluble complement inhibitors factor H and factor H-like protein (FHL-1) by ovarian tumour cells. Br J Cancer 2002; 87: 1119-1127. (Pubitemid 35418107)
35. Thurman JM, Holers VM,. The central role of the alternative complement pathway in human disease. J Immunol 2006; 176: 1305-1310. (Pubitemid 43134269)
36. Huang Y, Qiao F, Atkinson C, Holers VM, Tomlinson S,. A novel targeted inhibitor of the alternative pathway of complement and its therapeutic application in ischemia/reperfusion injury. J Immunol 2008; 181: 8068-8076.
37. He S, Atkinson C, Qiao F, Cianflone K, Chen X, Tomlinson S,. A complement-dependent balance between hepatic ischemia/reperfusion injury and liver regeneration in mice. J Clin Invest 2009; 119: 2304-2316.
38. Diepenhorst GM, van Gulik TM, Hack CE,. Complement-mediated ischemia-reperfusion injury: Lessons learned from animal and clinical studies. Ann Surg 2009; 249: 889-899.
39. Scoazec JY, Borghi-Scoazec G, Durand F, et al,. Complement activation after ischemia-reperfusion in human liver allografts: Incidence and pathophysiological relevance. Gastroenterology 1997; 112: 908-918. (Pubitemid 27113817)
40. Silva MA, Mirza DF, Murphy N, et al,. Intrahepatic complement activation, sinusoidal endothelial injury, and lactic acidosis are associated with initial poor function of the liver after transplantation. Transplantation 2008; 85: 718-725. (Pubitemid 351398249)
41. Charlesworth JA, Williams DG, Sherington E, Lachmann PJ, Peters DK,. Metabolic studies of the third component of complement and the glycine-rich beta glycoprotein in patients with hypocomplementemia. J Clin Invest 1974; 53: 1578-1587.
42. Greenstein JD, Peake PW, Charlesworth JA,. The kinetics and distribution of C9 and SC5b-9 in vivo: Effects of complement activation. Clin Exp Immunol 1995; 100: 40-46.
43. Ronholm E, Tomasdottir H, Runeborg J, et al,. Complement system activation during orthotopic liver transplantation in man. Indications of peroperative complement system activation in the gut. Transplantation 1994; 57: 1594-1597. (Pubitemid 24191634)
44. Bellamy MC, Gedney JA, Buglass H, Gooi JH, Leeds Liver Group. Complement membrane attack complex and hemodynamic changes during human orthotopic liver transplantation. Liver Transpl 2004; 10: 273-278. (Pubitemid 38240127)
45. He S, Atkinson C, Evans Z, et al,. A role for complement in the enhanced susceptibility of steatotic livers to ischemia and reperfusion injury. J Immunol 2009; 183: 4764-4772.
46. Scoazec JY, Delautier D, Moreau A, et al,. Expression of complement-regulatory proteins in normal and UW-preserved human liver. Gastroenterology 1994; 107: 505-516. (Pubitemid 24233327)
47. Mahaffey KW, Granger CB, Nicolau JC, et al,. Effect of pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to fibrinolysis in acute myocardial infarction: The COMPlement inhibition in myocardial infarction treated with thromboLYtics (COMPLY) trial. Circulation 2003; 108: 1176-1183. (Pubitemid 37099984)
48. Granger CB, Mahaffey KW, Weaver WD, et al,. Pexelizumab, an anti-C5 complement antibody, as adjunctive therapy to primary percutaneous coronary intervention in acute myocardial infarction: The COMplement inhibition in Myocardial infarction treated with Angioplasty (COMMA) trial. Circulation 2003; 108: 1184-1190. (Pubitemid 37099985)
49. APEX AMI Investigators, Armstrong PW, Granger CB, et al,. Pexelizumab for acute ST-elevation myocardial infarction in patients undergoing primary percutaneous coronary intervention: A randomized controlled trial. JAMA 2007; 297: 43-51. (Pubitemid 46041725)